Cargando…

Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages

Computed tomography (CT) scans are the gold standard to measure treatment success of non-small cell lung cancer (NSCLC) therapies. Here, we investigated the very early tumor response of patients receiving chemotherapy or targeted therapies using a panel of already established and explorative liquid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janke, Florian, Bozorgmehr, Farastuk, Wrenger, Sabine, Dietz, Steffen, Heussel, Claus P., Heussel, Gudula, Silva, Carlos F., Rheinheimer, Stephan, Feisst, Manuel, Thomas, Michael, Golpon, Heiko, Günther, Andreas, Sültmann, Holger, Muley, Thomas, Janciauskiene, Sabina, Meister, Michael, Schneider, Marc A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226444/ https://www.ncbi.nlm.nih.gov/pubmed/32290637 http://dx.doi.org/10.3390/cancers12040954

Ejemplares similares

Dynamic contrast enhanced MRI of pulmonary adenocarcinomas for early risk stratification: higher contrast uptake associated with response and better prognosis
por: Rheinheimer, Stephan, et al.
Publicado: (2022)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC
por: Schneider, Marc A., et al.
Publicado: (2018)

Screening von Risikogruppen wird bald Realität
por: Heußel, Gudula
Publicado: (2022)

Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2022)

Potential Roles of Acute Phase Proteins in Cancer: Why Do Cancer Cells Produce or Take Up Exogenous Acute Phase Protein Alpha1-Antitrypsin?
por: Janciauskiene, Sabina, et al.
Publicado: (2021)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma
por: Schneider, Marc A., et al.
Publicado: (2022)

Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-Antitrypsin Protein in NSCLC
por: Ercetin, Evrim, et al.
Publicado: (2019)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020)

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
por: Eichkorn, Tanja, et al.
Publicado: (2020)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients
por: Dietz, Steffen, et al.
Publicado: (2016)

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
por: Riediger, Anja Lisa, et al.
Publicado: (2016)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Unsupervised clustering algorithms improve the reproducibility of dynamic contrast-enhanced magnetic resonance imaging pulmonary perfusion quantification in muco-obstructive lung diseases
por: Konietzke, Marilisa, et al.
Publicado: (2022)

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2020)

Lung Adenocarcinoma Cell Sensitivity to Chemotherapies: A Spotlight on Lipid Droplets and SREBF1 Gene
por: Gründing, Anna Ricarda, et al.
Publicado: (2022)

Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency
por: Koczulla, A-Rembert, et al.
Publicado: (2012)

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2023)

Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients
por: von Eiff, Damian, et al.
Publicado: (2020)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

Diagnostic Radiology in Hematological Patients with Febrile Neutropenia
por: Heussel, Claus Peter
Publicado: (2014)

Pneumonia
por: Heussel, Claus Peter
Publicado: (2009)

Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer
por: Weber, Rebecca, et al.
Publicado: (2018)

Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2016)

Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas
por: Rieber, Juliane, et al.
Publicado: (2015)

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients
por: Nattenmüller, Johanna, et al.
Publicado: (2017)

A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
por: Lange, Ansgar, et al.
Publicado: (2014)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

Alpha1-antitrypsin protects lung cancer cells from staurosporine-induced apoptosis: the role of bacterial lipopolysaccharide
por: Schwarz, Natalie, et al.
Publicado: (2020)

CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation
por: Zhao, Jing, et al.
Publicado: (2017)

Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients
por: Reinmuth, Niels, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f2m8uhm12l66231laeebee98fs